$CGEM SEC Filings

Filed On	Filing
02 Oct 2026	8-K: Regulation FD Disclosure; Other Events New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program
24 Sep 2026	8-K: Regulation FD Disclosure; Other Events Velinotamig (BCMA TCE) multi-dose regimen data in SLE at ACR Convergence 2026 in November
14 Sep 2026	8-K: Regulation FD Disclosure; Other Events Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
10 Sep 2026	Form 4: Michaelson Jennifer, Chief Scientific Officer Received 4,000 shares by exercise or conversion ($17.2K) · Sold 8,000 shares ($173K)
08 Sep 2026	144
14 Aug 2026	Form 4: Michaelson Jennifer, Chief Scientific Officer Received 30,000 shares by exercise or conversion ($129K) · Sold 30,000 shares ($608K)
14 Aug 2026	SCHEDULE 13G/A
14 Aug 2026	SCHEDULE 13G
13 Aug 2026	144
13 Aug 2026	8-K: Regulation FD Disclosure; Other Events
07 Aug 2026	SCHEDULE 13G
06 Aug 2026	10-Q
06 Aug 2026	8-K: Results of Operations and Financial Condition
07 Jul 2026	Form 4: Michaelson Jennifer, Chief Scientific Officer Received 4,000 shares by exercise or conversion ($17.2K) · Sold 8,000 shares ($143K)
06 Jul 2026	144
02 Jul 2026	Form 4: Sumer Jacquelyn L, Chief Legal Officer Received 2,470 shares as a grant or award ($21.2K)
02 Jul 2026	Form 4: Fenton Mary Kay, Chief Financial Officer Received 1,541 shares as a grant or award ($13.3K)
18 Jun 2026	Form 4: Rosenberg Anthony, Director Granted 25,319 Stock Option (Right to Buy)
18 Jun 2026	Form 4: Meek David D., Director Granted 25,319 Stock Option (Right to Buy)
18 Jun 2026	Form 4: Webster Stephen W, Director Granted 25,319 Stock Option (Right to Buy)

Comments